APA (7th ed.) Citation

Roof, S. R., Ueyama, Y., Mazhari, R., Hamlin, R. L., Hartman, J. C., Ziolo, M. T., . . . del Rio, C. L. (2017). CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Frontiers in physiology, 8, 894. https://doi.org/10.3389/fphys.2017.00894

Chicago Style (17th ed.) Citation

Roof, Steve R., Yukie Ueyama, Reza Mazhari, Robert L. Hamlin, J. Craig Hartman, Mark T. Ziolo, John E. Reardon, and Carlos L. del Rio. "CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat." Frontiers in Physiology 8 (2017): 894. https://doi.org/10.3389/fphys.2017.00894.

MLA (9th ed.) Citation

Roof, Steve R., et al. "CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat." Frontiers in Physiology, vol. 8, 2017, p. 894, https://doi.org/10.3389/fphys.2017.00894.